Strategic partnerships CureLab Oncology is advancing Phase II trials for Elenagen globally and preparing US studies, presenting an opportunity to discuss research collaborations, co-development, or sponsored trials with CROs, academic centers, and pharma partners focused on oncology vaccines and immunotherapies.

Clinical expansion Recent international trial activity and a new CMO appointment signal readiness to engage medical affairs teams, KOLs, and translational partners for collaborative trials, advisory roles, and evidence generation programs targeting platinum-resistant ovarian cancer and other solid tumors.

Vaccine platform Elenagen utilizes a p62/SQSTM1 plasmid vaccine approach that can potentially pair with standard therapies; sales conversations can target oncology sites exploring combination regimens, adjunctive immunotherapies, and inflammation-modulating strategies.

Veterinary pathway CureLab Veterinary indicates a diversified distribution route and cross-species platform leverage; opportunities exist to discuss licensing, co-development, or distribution partnerships in veterinary oncology to broaden pipeline validation and revenue streams.

INVESTMENT READY With a reported revenue range and a lean team, CureLab presents as an attractive partner for early-stage investors or strategic buyers seeking a NPV-positive asset in oncology vaccines, enabling discussions around licensing, equity partnerships, or milestone-driven collaborations.